Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Humacyte, Inc.

Get SEC filing alerts via email and in your feed for Humacyte, Inc.

HUMA HUMAW

Humacyte, Inc.

About Humacyte, Inc.

Humacyte, Inc. develops bioengineered human tissues and acellular vascular grafts for medical use. Its core products include the FDA-approved Symvess ATEV for vascular repair, reconstruction, and replacement, targeting trauma, dialysis access, PAD, and cardiac surgery markets. The company leverages scalable manufacturing and proprietary technology to produce off-the-shelf, universally implantable tissues with low infection and rejection rates, aiming to improve patient outcomes and transform regenerative medicine.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Humacyte, Inc.

1
1
Humacyte, Inc. Humacyte Reports $495K Revenue in Q1 2026, Faces $17.6M Net Loss

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Humacyte, Inc. Humacyte Reports $40.8 Million Net Loss and $2.0 Million Revenue for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Humacyte, Inc. Humacyte Reports $753,000 Revenue in Q3 2025, Significant Year-Over-Year Growth

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Humacyte, Inc. Humacyte Reports $301,000 Revenue in Q2 2025, Significant Year-Over-Year Growth

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Humacyte, Inc. Humacyte Reports $517,000 Revenue and $39.1 Million Net Income in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Humacyte, Inc. Humacyte Reports $148.7 Million Net Loss for 2024, FDA Approves Symvess™

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Humacyte, Inc. Humacyte Reports Significant Financial Challenges, Net Loss Increases 51% in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments